Tevogen Bio Eyes Acquisition Of Global CRO To Add $20M+ Revenue And Fuel Growth Across Oncology, Rare Diseases, And Medical Devices

Tevogen Bio is in advanced evaluation to acquire a niche contract research organization (CRO) that operates in over 20 countries. This potential transaction is expected to add more than $20 million in annual revenue and support double-digit growth, enhancing Tevogen's capabilities in oncology, rare diseases, and medical devices. The acquisition aims to create a more diversified healthcare enterprise with complementary expertise and a focus on high-quality solutions.